Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06884618 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
A Phase 1 study of Neoplasms, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 345
- Enrollment target
- 19
- Study locations
NCT06884618 is a Phase 1 study of Neoplasms that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 345 participants, below the 1,619-participant average among 158 other Neoplasms trials with a reported enrollment target (79% lower). The trial reports 19 study locations across 10 states.
The verdict
NCT06884618, a Phase 1 study of Neoplasms, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 345 participants
- Enrollment target
- 19
- Study locations
Study Summary
This study aims to evaluate the safety and tolerability of RO7673396 in participants with advanced solid tumors harboring RAS mutation(s). This study consists of two stages: Stage 1 (Dose Escalation) and Stage 2 (Dose Expansion). Stage 1 will define the recommended dose(s) for expansion (RDEs) of RO7673396. Stage 2 will evaluate preliminary anti-tumor activity of the RDE(s) defined in Stage 1 and of other doses of interest for future development in selected solid tumor indications.
Conditions Studied
Interventions
- DRUG RO7673396
Study Locations (19)
Other
- Sun Yat-Sen University Cancer Center;Department of Thoracic Surgery - Guangzhou
- Fudan University Shanghai Cancer Center - Shanghai
- Hubei Cancer Hospital - Wuhan
- Prince of Wales Hospital - Hong Kong
- New Zealand Clinical Research - Auckland - Auckland
- New Zealand Clinical Research - Christchurch - Christchurch
- National Cancer Centre - 30 Hospital Blvd - Singapore
- National Cheng Kung University Hospital - Tainan
- National Taiwan University Hospital - Taipei
Texas
- MD Anderson Cancer Center - Houston
- South Texas Accelerated Research Therapeutics (START) - San Antonio
California
- City of Hope Comprehensive Cancer Center - Duarte
Colorado
- University of Colorado - Anschutz Medical Campus - PPDS - Aurora
Connecticut
- Smilow Cancer Hospital at Yale New Haven - New Haven
Florida
- Florida Cancer Specialists - Sarasota (North Catttlemen Rd) - Sarasota
New South Wales
- St Vincent's Hospital Sydney - Darlinghurst
Victoria
- Peter MacCallum Cancer Center - Parkville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 345 participants |
| Start Date | 2025-04-30 |
| Est. Completion | 2029-05-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06884618
The ClinicalTrials.gov registry entry for NCT06884618 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 345 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,619-participant average among 158 other Neoplasms trials with a reported enrollment target (79% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which RO7673396 is the first listed.
NCT06884618 reports 19 study locations spanning 10 distinct geographic areas - top geographies include Other, Texas, California.
Frequently Asked Questions
What is clinical trial NCT06884618 about?
NCT06884618 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)". This study aims to evaluate the safety and tolerability of RO7673396 in participants with advanced solid tumors harboring RAS mutation(s). This study consists of two stages: Stage 1 (Dose Escalation) and Stage 2 (Dose Expansion). Stage 1 will define the recommended dose(s) for expansion (RDEs) of RO...
What is the current status of trial NCT06884618?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 345 participants. The study started on 2025-04-30. Estimated completion is 2029-05-25.
What conditions does trial NCT06884618 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT06884618?
The interventions under investigation include: RO7673396 (DRUG).
Who is sponsoring clinical trial NCT06884618?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06884618 being conducted?
This trial has 19 study locations across California, Colorado, Connecticut, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
-
Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.